Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMNICELL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMNICELL's regulatory disclosures and financial reporting.
Randall A. Lipps, chairman and CEO of Omnicell, Inc., reported an indirect sale of 10,000 shares of common stock on July 15, 2026 at $47.00 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
After this transaction, a trust with his wife holds 345,861 shares indirectly, a separate trust for his children holds 8,051 shares indirectly, and he holds 523,184.0741 shares directly.
Njoku Nnamdi reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. President & COO Nnamdi Njoku received an equity award of 12,309 shares of common stock in the form of Restricted Stock Units (RSUs). These RSUs were granted under the company’s equity incentive plan in connection with his promotion effective July 1, 2026.
Following this award, Njoku holds a total of 167,094.4457 shares of common stock directly. One-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries, tying the award to multi‑year service.
Omnicell, Inc. announced that its Board appointed Nnamdi Njoku as President of the Company, effective July 1, 2026, while he continues as Chief Operating Officer. Randall A. Lipps stepped down from the President role but remains Chief Executive Officer and Chairman of the Board with no compensation changes.
Njoku will lead Omnicell’s long-term growth strategy and innovation roadmap, focusing on scaling global operations and advancing initiatives such as the Omnicell Titan XT automated dispensing system and the cloud-native OmniSphere platform. To support his expanded role, the Compensation Committee approved a one-time equity award of restricted stock units with a target grant date value of approximately $500,000, vesting over three years, while his 2026 base salary remains $661,000 with a target cash bonus equal to 100% of salary.
Omnicell, Inc. director Eileen J. Voynick received a grant of 4,785 shares of common stock as restricted shares for her services on the Board of Directors under the company’s equity incentive plan. The award carries no cash exercise price and will vest in full on the one-year anniversary of the grant date. Following this grant, she directly holds 20,011 shares of Omnicell common stock.
Seim Robin Gene reported acquisition or exercise transactions in this Form 4 filing.
Omnicell director Robin Gene Seim received a grant of 4,845 shares of common stock as equity compensation. The shares are restricted and were awarded under Omnicell's equity incentive plan for service on the Board of Directors.
These restricted shares will vest in full on the one-year anniversary of the grant date. Following this award, Seim directly holds a total of 52,198 shares of Omnicell common stock.
Scott Bruce E reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. director Scott E. Bruce received a grant of 4,627 shares of Common Stock as equity compensation for his service on the board. The grant was made at no cash cost to him and was issued under the company’s equity incentive plan. Following this award, he directly holds 27,600 shares. The restricted shares are scheduled to vest in full on the one-year anniversary of the grant date, tying his compensation to the company’s longer-term performance.
Bousa Edward Peter reported acquisition or exercise transactions in this Form 4 filing.
Omnicell, Inc. director Edward Peter Bousa received a grant of 4,603 shares of Common Stock as restricted shares under the company’s equity incentive plan. The award was given as consideration for his services as a Board member and will vest in full on the one-year anniversary of the grant date.
After this grant, Bousa directly holds a total of 22,589 shares of Omnicell common stock.
Bauer Joanne B reported acquisition or exercise transactions in this Form 4 filing.
Omnicell director Joanne B. Bauer received a grant of 5,027 shares of common stock as equity compensation for her service on the Board of Directors. The restricted shares were granted at no cash cost per share and are scheduled to vest in full on the one-year anniversary of the grant date. Following this award, Bauer directly holds 49,922 shares of Omnicell common stock.
PARRISH MARK W reported acquisition or exercise transactions in this Form 4 filing.
Director Mark W. Parrish of OMNICELL, INC. received a grant of 4,845 shares of common stock on June 1, 2026. The shares were awarded at $0.00 per share under the company’s equity incentive plan as compensation for his service on the Board.
These are restricted shares that will vest in full on the one-year anniversary of the grant date, meaning Parrish must remain in his board role for a year to receive them outright. After this grant, he holds 70,100 common shares directly. This is a compensation-related award, not an open-market stock purchase.